Clinical trial
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously…
NCT00160706 · UCB Pharma SA, Industry · Completed
Key facts
| NCT number | NCT00160706 |
|---|---|
| Title | A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease |
| Official title | A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients… |
| Acronym | PRECiSE 4 |
| Lead sponsor | UCB Pharma SA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | Certolizumab Pegol (CDP870) |
| Enrollment | 310 |
| Start date | Feb 1, 2004 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 7, 2018 |
| Countries | Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: